Pfizer will use Ichor Medical Systems devices for cancer vaccine development

Ichor Medical Systems said it will develop electroporation devices for use in Pfizer's ($PFE) preclinical cancer vaccine research efforts. Neither side is disclosing financial details, but San Diego-based Ichor gets an upfront payment plus milestone and royalty cash based on potential future sales. Both sides will share some development expenses. Ichor is known for its TriGrid Delivery System, an integrated and fully automated device for electroporation-mediated DNA administration in humans. The technology enables the delivery of DNA drugs and vaccines for diseases such as cancer, malaria, hepatitis B and HIV, Ichor said. Release

Suggested Articles

The FDA disclosed over 60 safety reports related to intra-aortic balloon pumps manufactured by Maquet and Datascope, following a recall this summer.

Truvian Sciences raised $27.1 million to fuel the development of its benchtop blood tester, bringing the company’s total funding to $46.3 million.

The money will fund work to develop polymers in multiple indications and an associated U.S. expansion.